

-NKEQHLSSENPVDTNSDNNLFTDTDLK-	503-529	18
-EMDDVAIEDEVLEQLFK-	552-558	19
-MDIETNDTFSDEAVPESSK-	595-613	20
-ELKEDSWAK-	625-635	21
-KLLLTEFR-	653-660	22
-NPSGINDDYGQLK- ^c	671-683	23
-EESLADDLFR-	736-745	24

^aMass spectrometry is unable to distinguish L/I and Q/K. The indication of L, I, Q, and K residues in the peptide sequences is based on the p95 ORF.

^bNumbering system is based on the ORF of the p95 cDNA.

^cThis peptide was sequenced by tandem mass spectrometry and used for EST database searches. The remaining peptides corresponded to the derived amino acid sequence from the p95 ORF.

Remarks

This Supplemental Preliminary Amendment and the above-referenced SEQUENCE LISTING are filed to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821-1.825. To conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 through 1.825, a paper copy of a Sequence Listing is submitted herewith. The paper copy of the Sequence Listing in this application is identical to the computer readable form of the Sequence Listing filed in application Serial No. 09/067,641, filed April 27, 1998. In accordance with 37 C.F.R. § 1.821(e), please use the computer readable form filed on December 3, 1999 in application Serial No. 09/067,641 as the computer readable form for the instant application.

The amendments to the specification, adding sequence identifiers, are made to conform the above-referenced application to the requirements of 37 C.F.R. § 1.821(d). It is respectfully submitted that these amendments do not represent new matter.